⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
7MM Human Immunodeficiency Virus (HIV) Drug Forecast and Market Analysis Report 2026: Pipeline STRs Will Not Surpass Biktarvy in Terms of Commercial Success - Outlook to 2033
globenewswire.com
GILD
GSK
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
accessnewswire.com
NNVC
GILD
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
globenewswire.com
AZN
ABBV
GILD
BMY
FDA Grants Accelerated Approval to Gilead’s Hepcludex ® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
businesswire.com
GILD
Gilead Receives CHMP Positive Opinion for Trodelvy ® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
businesswire.com
GILD
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
businesswire.com
GILD
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
businesswire.com
GILD
SIAM Announces Dr. Magnus Fontes as 2026 I. E. Block Community Lecture Speaker
globenewswire.com
GILD
Hepatic Impairment Market Analysis Report 2026-2036 Featuring AbbVie, Astellas Pharma, Gilead Sciences, F. Hoffmann La Roche, and Takeda Pharmaceuticals
globenewswire.com
GILD
BMY